Business
Todos Medical to Present at January 5, 2022 Emerging Growth Conference
Todos Medical to Present at January 5, 2022 Emerging Growth Conference.
About this update from Todos Medical Ltd.
[{"type":"text","content":"\n NEW YORK, NY and TEL AVIV, Israel, Jan. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that Todos Medical President & CEO Gerald Commissiong will be presenting at the upcoming Emerging Growth Conference to be held on January 5, 2022. The following are details for the conferences: Event: Emerging Growth Conference Date: January 5, 2022 Registration: https://goto.webcasts.com/starthere.jsp?ei=1518570&tp_key=bbd5fd57f5&sti=tomdf  Time: 12:00 pm EST This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company’s CEO, Gerald Commissiong in real time.  For more information, please visit www.todosmedical.com. For more information on the Company’s CLIA/CAP certified lab Provista Diagnostics, Inc. please visit www.provistadx.com.  About Todos Medical, Ltd.  Founded in Rehovot, Israel with offices in New York City, Todos Medical, Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos recently acquired U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and Provista's proprietary commercial-stage Videssa® breast cancer blood test.  Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result o...